Related Experiment Video

Updated: Jul 5, 2026

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
11:17

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays

Published on: January 7, 2016

Recombinant human growth hormone for children born small for gestational age: meta-analysis confirms the consistent

R Crabbé1, M von Holtey, P Engrand

  • 1Debiopharm SA, Lausanne, Switzerland.

Journal of Endocrinological Investigation
|May 14, 2008
PubMed

Insights

Higher doses of recombinant human growth hormone (r-hGH) improve growth in short children born small for gestational age (SGA). Treatment with Serono

Area of Science:

  • Pediatric Endocrinology
  • Growth Hormone Therapy
  • Biopharmaceuticals

Background:

  • Optimal recombinant human growth hormone (r-hGH) dosing for short children born small for gestational age (SGA) remains under investigation.
  • Children born SGA often experience growth deficits requiring therapeutic intervention.

Purpose of the Study:

  • To determine the dose-response relationship of r-hGH in short children born SGA.
  • To evaluate the efficacy of a specific r-hGH formulation (Serono) at a standard dose.

Main Methods:

  • Meta-analysis of clinical trials involving r-hGH treatment in SGA children.
  • Development of a mathematical model to describe the dose-response relationship.
  • Estimation and comparison of growth response (height-SDS gain) to different r-hGH doses and formulations.

Main Results:

  • A clear dose-response relationship was established, with higher r-hGH doses yielding greater height-SDS gain.
  • The higher dose (0.067 mg/kg/day) showed a mean difference of 0.48 SDS gain compared to the lower dose (0.033 mg/kg/day).
  • The Serono r-hGH formulation at 0.033 mg/kg/day demonstrated an estimated height-SDS gain of 1.2, consistent with other formulations.

Conclusions:

  • A significant dose-response relationship exists for r-hGH in treating short SGA children.
  • Treatment with Serono r-hGH formulation at 0.033 mg/kg/day is expected to yield a meaningful therapeutic outcome.
Abstract

More Related Videos

Midface Hypoplasia and Cranial Base Morphology in Syndromic Craniosynostosis: A Comparative Analysis Study Using a Predictive Regression Model08:03

Midface Hypoplasia and Cranial Base Morphology in Syndromic Craniosynostosis: A Comparative Analysis Study Using a Predictive Regression Model

Published on: November 4, 2025

Related Concept Videos

Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience, such as differences...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...